Johnson & Johnson $JNJ Stock Holdings Lowered by Burgundy Asset Management Ltd.

Burgundy Asset Management Ltd. trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,136,939 shares of the company’s stock after selling 23,141 shares during the period. Johnson & Johnson comprises approximately 1.9% of Burgundy Asset Management Ltd.’s investment portfolio, making the stock its 16th biggest position. Burgundy Asset Management Ltd.’s holdings in Johnson & Johnson were worth $201,431,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Norges Bank purchased a new stake in shares of Johnson & Johnson during the second quarter valued at $4,877,174,000. Laurel Wealth Advisors LLC raised its holdings in Johnson & Johnson by 15,040.6% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 7,420,699 shares of the company’s stock worth $1,133,512,000 after buying an additional 7,371,687 shares during the period. Vanguard Group Inc. lifted its stake in Johnson & Johnson by 1.3% during the second quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock valued at $36,209,060,000 after buying an additional 3,085,180 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Johnson & Johnson by 2.1% in the second quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock worth $9,227,988,000 after buying an additional 1,225,676 shares during the period. Finally, Legal & General Group Plc increased its position in shares of Johnson & Johnson by 6.2% in the second quarter. Legal & General Group Plc now owns 18,917,274 shares of the company’s stock worth $2,889,614,000 after acquiring an additional 1,097,855 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of several research analyst reports. Sanford C. Bernstein upped their price target on shares of Johnson & Johnson from $208.00 to $225.00 and gave the company a “market perform” rating in a research report on Friday, January 23rd. Leerink Partners increased their target price on Johnson & Johnson from $201.00 to $232.00 and gave the company a “market perform” rating in a report on Thursday, January 22nd. Rothschild & Co Redburn raised their target price on Johnson & Johnson from $180.00 to $210.00 and gave the stock a “neutral” rating in a research report on Thursday, February 19th. Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a research report on Wednesday, January 28th. Finally, Citigroup raised their price objective on Johnson & Johnson from $232.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $232.70.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Timothy Schmid sold 1,322 shares of the business’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $245.66, for a total value of $324,762.52. Following the completion of the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,251,310.02. The trade was a 4.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the transaction, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 30,142 shares of company stock valued at $7,360,528 over the last quarter. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Down 0.6%

JNJ opened at $245.28 on Thursday. The company has a market capitalization of $591.10 billion, a PE ratio of 22.20, a price-to-earnings-growth ratio of 2.44 and a beta of 0.34. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. Johnson & Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $251.71. The business has a 50-day moving average of $227.06 and a 200-day moving average of $203.31.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. The business had revenue of $24.28 billion during the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s payout ratio is presently 47.06%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA Fast Track for nipocalimab in systemic lupus erythematosus — The drug earned Fast Track designation supported by positive Phase 2 data and an ongoing Phase 3 study, which can accelerate review timelines and boosts the pharma pipeline narrative. Nipocalimab Fast Track PR
• Positive Sentiment: New direct-to-consumer drug sales channel — J&J launched a U.S. website to sell certain medications directly to uninsured or out-of-pocket patients, which may expand access and create a new revenue stream outside traditional pharmacy channels. Reuters: Direct-to-consumer site
• Neutral Sentiment: Oncology and other late-stage programs showing progress — Early pasritamig data and other oncology moves underpin higher long-term estimates, but timelines and commercial execution remain key variables. Yahoo: Pipeline & legal update
• Neutral Sentiment: Investor access and upcoming results — J&J scheduled its first-quarter results call for April 14; the call and Q1 metrics will be the next catalysts for guidance and near-term sentiment. Earnings call notice
• Neutral Sentiment: Dividend and income investor interest — J&J continues to be highlighted among top dividend/dividend-growth picks, supporting demand from income-focused investors even amid broader volatility. Dividend aristocrat piece
• Neutral Sentiment: Analyst stance: Hold with limited upside — Bank of America reiterated a Hold rating citing higher oncology-driven estimates but constrained upside, which may temper upside momentum despite pipeline wins. TipRanks: Hold rating
• Negative Sentiment: Bayer legal challenge over prostate cancer product claims — Bayer has initiated legal action related to prostate cancer product claims, introducing litigation risk and potential costs or reputational impact that investors dislike. Yahoo: Legal challenge mention

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.